Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Large unusual trading volume in Pfizer put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below its 10-year ...

Pfizer (PFE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Large unusual trading volume in Pfizer, Inc. (PFE) put options that expire 30 days from now signals investors' bullish outlook on PFE stock. It trades for just over 8 times earnings, well below ...

Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers. Shares of rival Pfizer Inc. were up 0.3% in premarket trades and Merck & Co.

Accenture downgraded to neutral amid soft bookings, weak guidance, and demand uncertainty. See here to know more on ACN stock ...

Johnson & Johnson shares jumped to their highest price in more than three months as the US-based healthcare group shrugged ...

Pfizer faces adjusted financial forecasts as analysts lower earnings expectations for FY2025, signaling cautious optimism.

Moderna shares surged 9.5% amid legal backlash against vaccine policy changes. Will it be a turning point for MRNA which is ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday.